Search clinical trials for: fixed dose combination

Total 35705 results

Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers

Healthy
Bristol-Myers Squibb

Completed

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

Hepatitis C

United States
Boehringer Ingelheim

Completed

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Hypertension
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Bristol-Myers Squibb

Completed

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (Atazanavir)

Human Immunodeficiency Virus Type 1 (HIV-1)

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Healthy
Pfizer

Completed

A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers

Healthy Volunteers

Singapore
Fundación Centro Nacional de Investigaciones Cardiovasculares...
Ferrer Internacional S.A.; Fundacion Clinic per a la Recerca Biomedica; World... and other collaborators

Completed

Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. (FOCUS)

Myocardial Infarction

Spain, Italy, Argentina, Brazil, Paraguay
Janssen Research & Development, LLC

Completed

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

Healthy Volunteers

United States
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects

Healthy
Bristol-Myers Squibb

Completed

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Hepatitis C

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

Healthy
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Boehringer Ingelheim

Completed

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

Hypertension

Belgium, Canada, Denmark, Finland, France, Korea, Republic of, Netherlands, Norway, Philippines, South Africa, Sweden, Taiwan
Boehringer Ingelheim

Completed

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

Hypertension

China
Boehringer Ingelheim

Completed

An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

Hypertension

China, Malaysia, Philippines
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components

Healthy

Germany
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
Almirall, S.A.

Completed

A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid

Asthma

Germany, United Kingdom
Boehringer Ingelheim

Completed

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

Hypertension

Australia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Hypertension

United States, Bulgaria, Czech Republic, France, Hungary, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Ukraine
Aristotle University Of Thessaloniki

Completed

24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination (BTFC)

Glaucoma

Greece
Sanofi

Completed

Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled (LEGEND)

Type 2 Diabetes Mellitus

Lebanon, Russian Federation, Ukraine
Takeda

Completed

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Essential Hypertension

Italy, Poland, Spain, Bulgaria, Serbia, Netherlands, Estonia, Hungary, Germany, Sweden, Lithuania, Slovakia, United Kingdom, France

3

Subscribe